This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Merck's Ebola Vaccine Ervebo Gets Approval in United States
by Zacks Equity Research
FDA grants approval to Merck's (MRK) Ervebo vaccine for active immunization of individuals 18 years and above to protect against Ebola virus disease caused by Zaire Ebola virus.
Powerful Proof Anyone Can Invest for an Early Retirement - December 20, 2019
by Zacks Equity Research
Accomplishing the financial cushion to retire early is a fantasy for most, but bringing that fantasy to reality is not as difficult as it sounds. If you are willing to make some serious lifestyle adjustments, it can be achievable.
Top Analyst Reports for JPMorgan, Boeing & NVIDIA
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase (JPM), Boeing (BA) and NVIDIA (NVDA).
Pfizer's Braftovi sNDA Accepted by FDA for Priority Review
by Zacks Equity Research
FDA grants priority review to Pfizer's (PFE) sNDA seeking approval of Braftovi in combination with Erbitux as a treatment for advanced colorectal cancer.
Novartis' Asthma Candidate Fails in LUSTER Phase III Studies
by Zacks Equity Research
Novartis' (NVS) asthma candidate, fevipiprant, fails to meet endpoint in the phase III LUSTER studies.
Myriad Genetics Presents Trial Outcomes in Breast Health
by Zacks Equity Research
Myriad Genetics' (MYGN) PRS enhances the detection of breast cancer risk in women having PV in high- and moderate-penetrance breast cancer genes.
GlaxoSmithKline (GSK) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
GlaxoSmithKline (GSK) closed the most recent trading day at $45.93, moving -0.78% from the previous trading session.
Gilead Teams Up With Kiniksa, Submits BLA for CAR T Therapy
by Zacks Equity Research
Gilead (GILD) collaborates with Kiniksa for a combination study and submits BLA for CAR T therapy candidate.
Iterum Down as Sulopenem Antibiotic Fails in Phase III Study
by Zacks Equity Research
Iterum's antibiotic candidate, sulopenem, fails to meet the primary endpoint of non-inferiority to Merck's Invanz in a late-stage study, evaluating it in complicated intra-abdominal infections.
Roche's (RHHBY) sBLA for Asthma Drug Xolair Accepted by FDA
by Zacks Equity Research
The FDA accepts Roche's (RHHBY) allergic asthma drug Xolair's sBLA for the treatment of nasal polyps in adult patients aged 18 years or above with inadequate response to intranasal corticosteroids.
Gilead (GILD) Announces Positive Long-Term Data on Yescarta
by Zacks Equity Research
Gilead (GILD) announces positive long-term data from a mid-stage study on Yescarta in adult patients with refractory large B-cell lymphoma.
Pharma Stock Roundup: FDA Updates for RHHBY, AZN, MRK, No Asbestos in Talc Says JNJ
by Kinjel Shah
The FDA approves Roche's (RHHBY) Tecentriq for expanded use. It grants priority review status to AstraZeneca (AZN) & Merck's (MRK) supplemental applications.
AstraZeneca's Lynparza Gets China Nod in First-Line Setting
by Zacks Equity Research
AstraZeneca's (AZN) Lynparza receives approval in China for first-line maintenance treatment of advanced ovarian cancer with BRCA-mutation.
Glaxo Files NDA for Fostemsavir for Heavily Pre-Treated HIV
by Zacks Equity Research
Glaxo (GSK) submits a new drug application to the FDA for its first-in-class attachment inhibitor fostemsavir, which is being evaluated for the treatment of HIV-1 infection.
Are You Looking for a Top Momentum Pick? Why GlaxoSmithKline (GSK) is a Great Choice
by Zacks Equity Research
Does GlaxoSmithKline (GSK) have what it takes to be a top stock pick for momentum investors? Let's find out.
Bristol-Myers' Orencia Gets Breakthrough Therapy Tag for GvHD
by Zacks Equity Research
The FDA grants Breakthrough Therapy designation to Bristol-Myers Squibb's (BMY) Orencia for the prevention of moderate-to-severe acute GvHD in hematopoietic SCT from unrelated donors.
Is GlaxoSmithKline (GSK) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Bristol-Myers' Reblozyl to be Reviewed by FDA Committee
by Zacks Equity Research
Bristol-Myers (BMY) and Acceleron Pharma Inc.'s sBLA for Reblozyl in patients with myelodysplastic syndromes will be reviewed by the FDA's Oncologic Drugs Advisory Committee.
Epizyme Announces FDA Committee Review of Tazemetostat NDA
by Zacks Equity Research
Epizyme (EPZM) announces that the FDA committee will review its NDA for lead candidate, tazemetostat, on Dec 18.
Merck's Keytruda Gets FDA's Priority Tag in Bladder Cancer
by Zacks Equity Research
Merck's (MRK) sBLA for Keytruda gets FDA's priority review status to treat certain patients with high-risk, non-muscle invasive bladder cancer.
Large-Cap Pharmaceuticals Industry Prospects Bright for 2020
by Kinjel Shah
The Zacks Large Cap Pharmaceuticals industry ranks in the top 13% of more than 250 Zacks industries.
The Zacks Analyst Blog Highlights: Apple, Comcast, NVIDIA, GlaxoSmithKline and Global Payments
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Apple, Comcast, NVIDIA, GlaxoSmithKline and Global Payments
Top Analyst Reports for Apple, Comcast & NVIDIA
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), Comcast Corporation (CMCSA) and NVIDIA Corporation (NVDA).
Novo Nordisk Inks Deal With Dicerna to Develop RNAi Therapies
by Zacks Equity Research
Novo Nordisk (NVO) inks deal with Dicerna Pharmaceuticals to discover and develop novel therapies for the treatment of liver-related cardio-metabolic diseases.
Roche Gets CHMP Opinion for Breast Cancer & Lymphoma Drugs
by Zacks Equity Research
Roche's (RHHBY) breast cancer candidate and lymphona candidate get positive CHMP opinion. The company inks a deal to acquire Promedior, Inc.